Handelsavisen
prelaunch
Companies Healthcare MDNC.PK
MD
MDNC.PK OTC Diversified Medical Equipment & Supplies

Mdnc.Pk

$5,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
35,0 %
ROE
50,6 %
Net margin
23,7 %
Debt / equity
0,22
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-09-28
Ex-dividend
TR 1Y
About

MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.

Business. MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-09-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
50,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MDNC.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MDNC.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-09-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    MDNC.PK operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its customers.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    MDNC.PK maintains a strong liquidity position with a current ratio of 4.27, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of $877,830 and free cash flow of $2,233,320. The debt-to-equity ratio of 0.22 reflects a conservative capital structure, with long-term debt amounting to $940,280 against total equity of $4,270,830.

    In terms of profitability, MDNC.PK demonstrates a return on equity (ROE) of 50.56% and a return on assets (ROA) of 31.72%, both of which are significantly higher than the industry median for medical equipment and supplies. The company's net income of $2,159,470 and operating income of $3,191,500 highlight its strong earnings performance. Gross profit of $4,860,790 further supports the company's ability to maintain healthy margins in a competitive industry.

    MDNC.PK's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in the healthcare services and equipment sector.

    The company's growth trajectory is supported by a strong free cash flow and operating cash flow, which provide flexibility for reinvestment or shareholder returns. However, the outlook for the current fiscal year does not include specific numeric deltas for revenue growth, and the next fiscal year's direction remains unquantified in the available data.

    The risk assessment for MDNC.PK indicates a low dilution potential, with no significant dilution sources identified in the risk assessment or recent filings. The company's liquidity risk is rated as medium, primarily due to its negative net cash position after subtracting total debt. No major risk factors or dilution events are disclosed in the available documents, suggesting a relatively stable capital structure.

    Recent events and filings for MDNC.PK do not include any material disclosures or transcripts that would indicate significant changes in the company's operations or financial position. The absence of recent events suggests a stable and predictable business environment for the company.

    Key takeaways
    • MDNC.PK has a strong liquidity position with a current ratio of 4.27 and a conservative debt-to-equity ratio of 0.22.
    • The company's profitability is robust, with a return on equity of 50.56% and a return on assets of 31.72%.
    • MDNC.PK's revenue is concentrated in a single business segment, which may increase its exposure to sector-specific risks.
    • The company's growth is supported by strong free and operating cash flows, but no specific growth targets are disclosed for the current or next fiscal year.
    • The risk assessment indicates a low dilution potential and a medium liquidity risk, with no major risk factors identified in the available data.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $5,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.3M
    Net cash
    -$940.3k
    Current ratio
    4.3
    Debt / equity
    0.2
    ROA
    31.7%
    ROE
    50.6%
    Cash conversion
    41.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Airway & Respiratory Devices
    low · business_description · 2026-07-04
    Cardiovascular Devices
    low · business_description · 2026-07-04
    Medical Product Distribution
    low · business_description · 2026-07-04

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setMDNC 0,0% · rank #69 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs MDNC · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin35,0 %Above P75
    Net Margin23,7 %Above P75
    ROE50,6 %Best in class
    D/E0,22Above median
    Cash Conv0,41Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • MDNC.PK Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MDNC.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • EPS (basic) (YoY) (2026-02-28 vs 2025-02-28): -61.1%Derived (calculated)
    • Capex (YoY) (2026-02-28 vs 2025-02-28): 101.5%Derived (calculated)
    • Cost of revenue (YoY) (2026-02-28 vs 2025-02-28): 208.2%Derived (calculated)
    • R&D expense (YoY) (2026-02-28 vs 2025-02-28): 264.4%Derived (calculated)
    • Operating income (YoY) (2026-02-28 vs 2025-02-28): -65.7%Derived (calculated)
    • Operating cash flow (YoY) (2026-02-28 vs 2025-02-28): 3.3%Derived (calculated)
    • Net income (YoY) (2026-02-28 vs 2025-02-28): -63.2%Derived (calculated)
    • Gross profit (YoY) (2026-02-28 vs 2025-02-28): 5.5%Derived (calculated)
    • Revenue (YoY) (2026-02-28 vs 2025-02-28): 6.8%Derived (calculated)
    • Net margin (FY 2026-02-28): 8.2%Derived (calculated)
    • Gross margin (FY 2026-02-28): 52.7%Derived (calculated)
    • EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
    • Capex (annual): USD 1.36KSEC XBRL filing
    • Net income (annual): USD 794.5KSEC XBRL filing
    • Gross profit (annual): USD 5.13MSEC XBRL filing
    • Total operating expenses (annual): USD -4.03MSEC XBRL filing
    • Revenue (annual): USD 9.73MSEC XBRL filing
    • Operating cash flow (annual): USD 906.8KSEC XBRL filing
    • R&D expense (annual): USD 149.86KSEC XBRL filing
    • Operating income (annual): USD 1.09MSEC XBRL filing
    • Pre-tax income (annual): USD 1.07MSEC XBRL filing
    • Cost of revenue (annual): USD 4.6MSEC XBRL filing
    • Interest expense (annual): USD 87.59KSEC XBRL filing
    • Shareholders' equity (YoY) (2025-11-30 vs 2024-11-30): 94.6%Derived (calculated)
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-09-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage